Verapamil - Eisai

Drug Profile

Verapamil - Eisai

Alternative Names: E-0103; Vasolan

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Developer Eisai Co Ltd
  • Class Antihypertensives; Antimigraines; Class IV antiarrhythmics; Ischaemic heart disorder therapies; Nitriles; Phenethylamines; Small molecules; Vasodilators
  • Mechanism of Action Calcium channel antagonists; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atrial fibrillation; Ischaemic heart disorders; Paroxysmal supraventricular tachycardia; Supraventricular tachycardia

Most Recent Events

  • 21 Mar 2013 Chemical structure added (USAN); str saved as MOL and PNG files
  • 21 May 2011 Registered for Supraventricular tachycardia in Japan (PO)
  • 20 May 2011 Registered for Supraventricular tachycardia in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top